arrow
L

Lana Kambeitz-Ilankovic

University of Cologne
H指数:28
被引数:3,185

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High-Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

揭示全球临床高风险精神分裂症个体中的自杀意念与行为:多变量相关因素和阈下精神病症状

2026-09-130
OAAI
Disentangling white matter correlates of symptom severity and general impairment in early psychosis

早期精神分裂症中症状严重程度和总体功能损害的白质相关因素解构

2026-08-200
OA
Processing Speed and Verbal Learning Ability as Predictors of Assessor-Rated and Ecological Momentary Assessment Self-Reported Functioning: Findings from AMP SCZ

处理速度和言语学习能力作为评估者评定和生态瞬时评估自报功能表现的预测因素:AMP SCZ的研究发现

2026-08-030
PRE
Cognitive trajectories in the nine months following recent-onset major depressive disorder

近期发作重度抑郁症后九个月内的认知轨迹

2026-08-010
OAAI
Disrupted hierarchical functional brain organization in affective and psychotic disorders: insights from functional brain gradients

情感和精神病障碍中分层功能脑组织的破坏:来自功能脑梯度的见解

2026-07-290
OA
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative

收集语言、语音声学和面部表情数据以预测精神分裂症及其他临床结果:AMP® SCZ倡议的策略

2025-10-150
OAAI
Decoding Psychosis Risk: Neuroanatomical Correlates of the NAPLS-2 Calculator in the PRONIA Cohort

解码精神病风险:NAPLS-2计算器在PRONIA队列中的神经解剖学相关性

2025-08-010
PRE
From Snapshots to Stable Outcomes: rs-fMRI-based Prognosis of Functioning in Patients with Psychosis Risk or Recent-Onset Depression

从快照到稳定结果:基于rs-fMRI的功能表现预后预测,用于精神风险或近期发作抑郁症患者

2025-07-090
OAAI
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

加速药品合作计划®精神分裂症项目中的脑电图协议:测量指标的可靠性与稳定性

2025-06-060
OAAI
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

加速药物合作®精神分裂症计划中的数字健康技术

2025-06-030
OAAI
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

加速药物伙伴关系中的认知评估®精神分裂症计划: 在不同的国际样本中协调优先事项和策略

2025-03-240
OAAI
Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership—Schizophrenia

临床高风险精神病患者的大规模国际样本中,预后调整问题、阴性症状和认知障碍:来自加速药物合作计划—精神分裂症的研究结果

2025-01-010
OA
Neurocognitive dysfunction in adolescents with recent onset major depressive disorder: a cross-sectional comparative study

新近发作的重度抑郁症青少年的神经认知功能障碍: 一项横断面比较研究

2024-11-060
OAAI
Anhedonia as a Potential Transdiagnostic Phenotype With Immune-Related Changes in Recent-Onset Mental Health Disorders

在最近发作的精神卫生疾病中,hedonia是一种潜在的反式诊断表型,具有免疫相关变化

2024-10-011
OAAI
Alterations of Functional Connectivity Dynamics in Affective and Psychotic Disorders

情感和精神病性障碍中功能连接动力学的改变

2024-08-010
OAAI
Neurocognitive skills and vulnerability for psychosis in depression and across the psychotic spectrum: findings from the PRONIA Consortium (vol 223, pg 485, 2023)

抑郁症和整个精神病谱中的神经认知技能和精神病的脆弱性: PRONIA财团的发现 (223卷,485页,2023页)

2024-03-180
OA
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

加速药物伙伴关系®精神分裂症 (AMP®SCZ): 最大的全球精神病临床高风险前瞻性队列研究的基本原理和研究设计

2024-03-0712
OAAI